EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A multiparametric in vitro strategy for small molecule drug-induced liver injury risk mitigation in early drug development

Leah M Norona iD, Fjodor Melnikov iD, Tomomi Kiyota iD, Christopher Lawson, Cyrus Khojasteh iD, Joyce Liu iD, Kevin Johnson iD, Tony Pourmohamad, Lennart T Anger, William R Proctor iD, Aaron M Fullerton iD

Toxicological Sciences · 2026

DOI: 10.1093/toxsci/kfag124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicological Sciences, 2026. Verfasst von Leah M Norona und 10 weiteren Autor:innen. Beteiligte Einrichtung: Predictive Toxicology, Translational Safety, Genentech, Inc, South San Francisco, CA 94080, United States. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Hepatocytes, Drug Development. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genentech, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-induced liver injury (DILI) remains a major cause of preclinical and clinical attrition, reflecting persistent gaps in the predictive translation of preclinical safety data to human outcomes. To address these gaps, we established a refined multiparametric framework for early DILI risk prediction using a balanced reference set of 170 drugs with established clinical outcomes. Thirty physicochemical, mechanistic endpoints, and exposure-related features were systematically evaluated to identify high-specificity predictors of intrinsic DILI risk. Cytotoxicity in primary human hepatocytes and human liver microtissues, mitochondrial toxicity (i.e. mitotoxicity), and bile salt export pump inhibition were identified as top predictive features. Incorporation of clinical exposure data to derive margins of safety substantially improved assay performance, emphasizing the importance of exposure normalization. A multiparametric, flag-based hazard framework integrating ≥2 hazard flags achieved 98% specificity and a positive likelihood ratio of 18, providing a pragmatic approach for early compound triage and confidence in early decision-making. Random Forest models further enhanced predictive performance, identifying exposure, predicted lipophilicity (e.g. cLogD), mitotoxicity, cytotoxicity, and hepatic clearance as major contributors to DILI risk, with exposure-informed models achieving a balanced accuracy of 0.72. Application of the framework to contemporary Genentech portfolio molecules demonstrated translational utility in refining risk categorization, particularly for compounds with borderline or 0-1 hazard flags. Collectively, this work establishes a mechanistically informed and machine learning-enabled platform that combines interpretability, specificity, and practicality to guide safer molecule design in drug discovery and reduce hepatotoxicity-related attrition in clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemical and Drug Induced Liver InjuryHepatocytesDrug DevelopmentHumansRisk AssessmentLiverCells, Cultured

Stichwörter der Autor:innen

DILIdrug discoveryhepatotoxicityin vitro modelspredictive toxicology

Autor:innen und Institutionen

  • Predictive Toxicology, Translational Safety, Genentech, Inc, South San Francisco, CA 94080, United States.
  • Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc, South San Francisco, CA 94080, United States.
  • Investigative ADME/Toxicology & Bioanalytical Research Labs, Eli Lilly and Company, Indianapolis, IN 46285, United States.
  • Non-Clinical Biostatistics, Product Development, Genentech, Inc, South San Francisco, CA 94080, United States.
  • Non-Clinical Safety, Preclinical Sciences, Research and Development, GlaxoSmithKline, Waltham, MA 02451, United States.

ORCID-Profile: Leah M Norona, Fjodor Melnikov, Tomomi Kiyota, Cyrus Khojasteh, Joyce Liu, Kevin Johnson, William R Proctor, Aaron M Fullerton

Förderung

  • Genentech, Inc

Zitieren

APA

Norona, L. M., Melnikov, F., Kiyota, T., Lawson, C., Khojasteh, C., Liu, J., Johnson, K., Pourmohamad, T., Anger, L. T., Proctor, W. R., & Fullerton, A. M. (2026). A multiparametric in vitro strategy for small molecule drug-induced liver injury risk mitigation in early drug development. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfag124

Vancouver

Norona LM, Melnikov F, Kiyota T, Lawson C, Khojasteh C, Liu J, et al. A multiparametric in vitro strategy for small molecule drug-induced liver injury risk mitigation in early drug development. Toxicological Sciences. 2026. doi:10.1093/toxsci/kfag124

BibTeX
@article{Norona2026,
  author = {Norona, Leah M and Melnikov, Fjodor and Kiyota, Tomomi and Lawson, Christopher and Khojasteh, Cyrus and Liu, Joyce and Johnson, Kevin and Pourmohamad, Tony and Anger, Lennart T and Proctor, William R and Fullerton, Aaron M},
  title = {A multiparametric in vitro strategy for small molecule drug-induced liver injury risk mitigation in early drug development},
  journal = {Toxicological Sciences},
  year = {2026},
  doi = {10.1093/toxsci/kfag124}
}
Kostenlos starten →